HC Wainwright Has Negative Estimate for GLSI Q1 Earnings

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) – HC Wainwright reduced their Q1 2025 earnings per share (EPS) estimates for Greenwich LifeSciences in a note issued to investors on Monday, April 21st. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($0.24) for the quarter, down from their prior forecast of ($0.21). HC Wainwright has a “Buy” rating and a $39.00 price objective on the stock. The consensus estimate for Greenwich LifeSciences’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Greenwich LifeSciences’ Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.23) EPS and FY2025 earnings at ($0.94) EPS.

Greenwich LifeSciences Stock Performance

GLSI stock opened at $9.63 on Wednesday. The company’s fifty day moving average price is $10.77 and its 200-day moving average price is $12.31. Greenwich LifeSciences has a one year low of $8.06 and a one year high of $18.75. The company has a market capitalization of $127.83 million, a PE ratio of -12.04 and a beta of 1.76.

Greenwich LifeSciences (NASDAQ:GLSI) last posted its quarterly earnings results on Tuesday, April 15th. The company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.40).

Insider Buying and Selling at Greenwich LifeSciences

In other news, CEO Snehal Patel purchased 3,600 shares of the company’s stock in a transaction that occurred on Monday, April 7th. The stock was bought at an average cost of $9.10 per share, with a total value of $32,760.00. Following the completion of the purchase, the chief executive officer now owns 5,561,602 shares in the company, valued at approximately $50,610,578.20. This represents a 0.06 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last ninety days, insiders have purchased 14,500 shares of company stock worth $129,267. Insiders own 51.67% of the company’s stock.

Institutional Trading of Greenwich LifeSciences

Hedge funds have recently modified their holdings of the company. Wells Fargo & Company MN grew its holdings in shares of Greenwich LifeSciences by 54.8% in the fourth quarter. Wells Fargo & Company MN now owns 2,847 shares of the company’s stock valued at $32,000 after purchasing an additional 1,008 shares in the last quarter. Brown Brothers Harriman & Co. purchased a new position in shares of Greenwich LifeSciences in the 4th quarter worth $45,000. JPMorgan Chase & Co. grew its stake in shares of Greenwich LifeSciences by 172.0% in the 4th quarter. JPMorgan Chase & Co. now owns 7,061 shares of the company’s stock worth $79,000 after buying an additional 4,465 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of Greenwich LifeSciences by 22.3% in the 4th quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock worth $82,000 after buying an additional 1,322 shares during the last quarter. Finally, Rhumbline Advisers raised its position in shares of Greenwich LifeSciences by 48.7% during the 1st quarter. Rhumbline Advisers now owns 9,673 shares of the company’s stock valued at $92,000 after buying an additional 3,168 shares in the last quarter. 4.16% of the stock is owned by hedge funds and other institutional investors.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.